[eng] Scaffold proteins play key roles in assembling signaling molecules, facilitating their
localization, and coordinating feedback signals for pathway regulation. JIP-2, a scaffold
protein in the MAP kinase pathway, warrants exploration for its interaction with JNK-1
kinase, crucial in various cell signaling pathways and acknowledged for its interaction
with the D-motif of the JIP-1 scaffold protein. This research targets the 100-240aa region
of JIP-2, with the presence of a D-motif, to confirm and understand the interaction with
JNK-1.
Employing recombinant techniques using Escherichia coli as host microorganisms, JIP2 fragment, along with the JNK-1 and the TEV protease, were obtained through
expression plasmids. The purification of the recombinant proteins was conducted
through affinity chromatography using a nickel resin, due to its affinity for the histidinetag expressed alongside the recombinant proteins of interests. Furthermore, due to the
instability of the JNK-1 enzyme, the production and purification protocols were optimized
to ensure an ample quantity of the protein for subsequent studies.
The AlphaFold AI tool was used to predict the interaction between JIP-2 and JNK-1 and
associated residues, to compare theoretical and experimental outcomes. Experimental
verification involved SDS-PAGE electrophoresis and analysis of previously available JIP2 NMR data (2D- HSQCs, and 3D- HNCO, HNCACO, HNCOCACB and iHNCACB) for
assignment and NMR titration with JNK-1. Furthermore, chemical shifts and JIP-2
sequence were used to predict secondary structures and potential correlations with
complex formation. Interpretation of NMR data substantiated complex formation,
confirming D-motif interaction, like JIP-1. The region lacks secondary structure tendency,
except at the C-terminal end with a slightly alpha helix tendency and a possible binding
to JNK-1 via a non-D-motif. Nevertheless, further substantiation through subsequent
studies is required.
Understanding the interaction is vital to enhance knowledge of key signaling pathways
in neurodegenerative and cardiovascular diseases, cancer, and other conditions where
these proteins are present or involved.